VG Acquisition set a June 10 meeting for shareholders to vote on the SPAC’s proposed merger with 23andMe, a consumer genetics company.
The transaction will value the outstanding shares of 23andMe at an aggregate enterprise value of approximately $3.5 billion. The pro forma cash balance of the combined company will exceed $900 million at closing.
If approved, 23andMe Holding Co. shares and warrants are expected to trade on the Nasdaq under ME and “ME WS, respectively.
